AIM: To evaluate the association between the tumour necrosis factor alpha-308 (TNF-α-308) gene polymorphism and the risk of digestive system cancers. METHODS: All eligible case-control studies published up to December 2012 were identified by searching PubMed, Web of Science, Embase and China National Knowledge Internet without language restrictions. The risk of digestive system cancers associated with the TNF-α-308 polymorphism was estimated for each study using odds ratio (OR) together with its 95%CI, respectively. Cochrane Collaboration RevMan 5.1 was used to perform the analysis. A χ²-test-based Q statistic test and an I² test were performed to assess the between-study heterogeneity. When the Q test was significant (P < 0.05) or I² > 50%, the random effects model was used, otherwise the fixed effects model was used. RESULTS: Fifty-eight studies from fifty-five publications with a total of 9986 cancer patients and 15511 healthy controls were included. Overall, a significant association was found between the TNF-α-308 polymorphism and the risk of digestive system cancers [dominant model: OR = 1.23, 95%CI: 1.09-1.39, (G/A) vs (G/G): OR = 1.15, 95%CI: 1.02-1.28, (A/A) vs (G/G): OR = 1.44, 95%CI: 1.19-1.73, recessive model: OR = 1.38, 95%CI: 1.15-1.66]. Furthermore, when the analysis was stratified by ethnicity, similar results were observed in both the Asian and Caucasian populations, except for the dominant model and heterozygote comparisons in the Asian population [dominant model: OR = 1.24, 95%CI: 0.99-1.56, (G/A) vs (G/G): OR = 1.09, 95%CI: 0.96-1.24]. When the cancer type subgroups were examined, similar results were detected in gastric and hepatocellular carcinomas; however, no significant association was observed among other digestive system cancers. CONCLUSION: The TNF-α-308 gene polymorphism may be significantly associated with the risk of gastric and hepatocellular carcinomas, but not colorectal, pancreatic, or oesophageal cancer, in the Asian population.
AIM: To evaluate the association between the tumour necrosis factor alpha-308 (TNF-α-308) gene polymorphism and the risk of digestive system cancers. METHODS: All eligible case-control studies published up to December 2012 were identified by searching PubMed, Web of Science, Embase and China National Knowledge Internet without language restrictions. The risk of digestive system cancers associated with the TNF-α-308 polymorphism was estimated for each study using odds ratio (OR) together with its 95%CI, respectively. Cochrane Collaboration RevMan 5.1 was used to perform the analysis. A χ²-test-based Q statistic test and an I² test were performed to assess the between-study heterogeneity. When the Q test was significant (P < 0.05) or I² > 50%, the random effects model was used, otherwise the fixed effects model was used. RESULTS: Fifty-eight studies from fifty-five publications with a total of 9986 cancerpatients and 15511 healthy controls were included. Overall, a significant association was found between the TNF-α-308 polymorphism and the risk of digestive system cancers [dominant model: OR = 1.23, 95%CI: 1.09-1.39, (G/A) vs (G/G): OR = 1.15, 95%CI: 1.02-1.28, (A/A) vs (G/G): OR = 1.44, 95%CI: 1.19-1.73, recessive model: OR = 1.38, 95%CI: 1.15-1.66]. Furthermore, when the analysis was stratified by ethnicity, similar results were observed in both the Asian and Caucasian populations, except for the dominant model and heterozygote comparisons in the Asian population [dominant model: OR = 1.24, 95%CI: 0.99-1.56, (G/A) vs (G/G): OR = 1.09, 95%CI: 0.96-1.24]. When the cancer type subgroups were examined, similar results were detected in gastric and hepatocellular carcinomas; however, no significant association was observed among other digestive system cancers. CONCLUSION: The TNF-α-308 gene polymorphism may be significantly associated with the risk of gastric and hepatocellular carcinomas, but not colorectal, pancreatic, or oesophageal cancer, in the Asian population.
Authors: Florin Burada; Cristina Angelescu; Paul Mitrut; Tudorel Ciurea; Mihai Cruce; Adrian Saftoiu; Mihai Ioana Journal: Can J Gastroenterol Date: 2012-08 Impact factor: 3.522
Authors: Eric J Duell; Daniel P Casella; Robert D Burk; Karl T Kelsey; Elizabeth A Holly Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-04 Impact factor: 4.254
Authors: Megan M Garrity-Park; Edward V Loftus; Sandra C Bryant; William J Sandborn; Thomas C Smyrk Journal: Am J Gastroenterol Date: 2008-02 Impact factor: 10.864
Authors: J B A Crusius; F Canzian; G Capellá; A S Peña; G Pera; N Sala; A Agudo; F Rico; G Del Giudice; D Palli; M Plebani; H Boeing; H B Bueno-de-Mesquita; F Carneiro; V Pala; V E Save; P Vineis; R Tumino; S Panico; G Berglund; J Manjer; R Stenling; G Hallmans; C Martínez; M Dorronsoro; A Barricarte; C Navarro; J R Quirós; N Allen; T J Key; S Binghan; C Caldas; J Linseisen; R Kaaks; K Overvad; A Tjønneland; F C Büchner; P H M Peeters; M E Numans; F Clavel-Chapelon; A Trichopoulou; E Lund; M Jenab; S Rinaldi; P Ferrari; E Riboli; C A González Journal: Ann Oncol Date: 2008-07-14 Impact factor: 32.976
Authors: José Carlos Machado; Céu Figueiredo; Paulo Canedo; Paul Pharoah; Ralph Carvalho; Sérgio Nabais; Catarina Castro Alves; Maria Luisa Campos; Leen-Jan Van Doorn; Carlos Caldas; Raquel Seruca; Fátima Carneiro; Manuel Sobrinho-Simões Journal: Gastroenterology Date: 2003-08 Impact factor: 22.682
Authors: Bradley J Kendall; Louise F Wilson; Catherine M Olsen; Penelope M Webb; Rachel E Neale; Christopher J Bain; David C Whiteman Journal: Aust N Z J Public Health Date: 2015-10 Impact factor: 2.939
Authors: Claudia I Rivas-Ortiz; Yolanda Lopez-Vidal; Luis Jose Rene Arredondo-Hernandez; Gonzalo Castillo-Rojas Journal: Front Med (Lausanne) Date: 2017-05-02